Table 1.
Baseline characteristics
| Anti-PD1, any line | Anti-PD1, first line | |
| Number of patients | 819 | 557 |
| Age median (IQR) | 65 (55–73) | 67 (56–74) |
| Sex | ||
| Male | 472 (58%) | 327 (59%) |
| Female | 346 (42%) | 229 (41%) |
| WHO performance status | ||
| 0 | 454 (61%) | 332 (64%) |
| 1 | 256 (34%) | 166 (32%) |
| 2 | 36 (5%) | 21 (4%) |
| 3 | 2 (0%) | 2 (0%) |
| Number of comorbidities | ||
| 0 | 279 (34%) | 179 (32%) |
| 1–2 | 398 (49%) | 276 (50%) |
| ≥3 | 137 (17%) | 100 (18%) |
| Stage of disease | ||
| Unresectable stage III | 53 (7%) | 41 (8%) |
| IV, M1a | 77 (10%) | 55 (10%) |
| IV, M1b | 102 (13%) | 90 (17%) |
| IV, M1c | 360 (45%) | 250 (46%) |
| IV, M1d | 205 (26%) | 109 (20%) |
| Symptomatic brain metastases | 103 (13%) | 56 (10%) |
| Number of metastatic sites | ||
| 0 | 87 (11%) | 63 (12%) |
| 1 | 251 (33%) | 180 (35%) |
| 2 | 222 (29%) | 146 (28%) |
| 3 | 143 (19%) | 84 (16%) |
| 4 | 50 (7%) | 33 (6%) |
| 5 | 12 (2%) | 9 (2%) |
| 6 | 1 (0%) | 1 (0%) |
| LDH | ||
| ≤ULN | 548 (68%) | 369 (67%) |
| 1–2 × ULN | 210 (26%) | 155 (28%) |
| >2 × ULN | 50 (6%) | 27 (5%) |
| ICI treatment | ||
| Nivolumab | 261 (32%) | 178 (32%) |
| Pembrolizumab | 558 (68%) | 379 (68%) |
| Line of systemic therapy | ||
| 1 | 557 (68%) | |
| 2 | 208 (25%) | |
| 3 | 39 (5%) | |
| ≥4 | 15 (2%) |
ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; PD1, programmed cell death 1; ULN, upper limit of normal (defined as 250 U/L).